Simonovich, 333 patient convalescent plasma late treatment RCT: 4% lower mortality [p=1] and 19% improved 7-point scale results [p=0.4] https://c19p.org/simonovich
copied to clipboard
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
et al., NEJM, doi:0.1056/NEJMoa2031304
RCT 333 hospitalized patients in Argentina, 228 treated with convalescent plasma, showing no significant differences in clinical status or mortality. NCT04383535.
|
risk of death, 4.1% lower, RR 0.96, p = 1.00, treatment 25 of 228 (11.0%), control 12 of 105 (11.4%), NNT 216.
|
|
risk of 7-point scale, 19.0% lower, OR 0.81, p = 0.40, treatment 228, control 105, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Simonovich et al., 11/24/2020, Randomized Controlled Trial, Argentina, South America, peer-reviewed, 39 authors, average treatment delay 8.0 days, trial NCT04383535.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.